Newspaper logo  
Local News & Opinion

Ref. : Civic Events

Ref. : Arts & Education Events

Ref. : Public Service Notices

Books, Films, Arts & Education

10.06 Teachers vs. Prisons

Open Letters:

Ref. : Letters to the editor

Health Care & Environment

10.08 Cars, aviation, steel ... the stranded assets risk spreads far beyond fossil fuel firms

10.08 How a Manmade Tidal Lagoon Could Change the Future of Clean Energy

10.08 L.A.'s New 'Energy Atlas' Maps Who Sucks the Most Off the Grid

10.07 California governor signs bill legalizing physician-assisted suicide

10.07 The Clean-Energy Moonshot

10.06 The 4 Kinds of People Who Don’t Vaccinate Their Kids

10.06 Seven practical steps to protect our cities from the effects of climate change

10.06 Chile to Create One of World’s Largest Marine Parks

10.06 Citigroup Becomes Third Major Bank to Cut Financing to Coal Industry

News Media Matters

Daily: FAIR Blog
The Daily Howler

US Politics, Policy & 'Culture'

10.08 Planned Parenthood's Cecile Richards: 'In this election, Roe v Wade is on the ballot'

10.08 'The goal is to be the winner': Donald Trump's campaign is for real

10.08 The Future of U.S. Voting May Be U.K. Technology

10.07 The Counted: 'Forced to fire'

10.07 Gun demanding: the psychology of why people want firearms

10.07 Bill Ackman's latest wager: Bloomberg for president

10.07 The Populist Prophet

10.06 Stephen Colbert to Donald Trump: ‘There Is Zero Chance’ You’ll Be President [7:58 video]

10.06 Watch John Oliver Explain Broken U.S. Mental Health System [11:54 video]

Justice Matters

10.08 Donald Trump takes campaign against windfarms to UK supreme court

10.08 Can California Prevent Wage Discrimination Against Women?

High Crimes?

10.06 U.S. General Says Afghans Requested Airstrike That Hit Kunduz Hospital

Economics, Crony Capitalism

10.08 Hillary Clinton Abandons Obama on Trade

10.07 The Corporate-Friendly World of the T.P.P.

10.07 The Good (and Bad) News About Poverty and Global Trade

10.06 Obama faces TPP deal balancing act as Congress considers approval


10.08 In the Montréal Area, 82 Municipalities Begin to Think and Act As One

10.08 All You Need Is Love [An old, true story with a timeless, powerful lesson]

10.08 Ready or Not, the Third Intifada May Be Here [Dear Netanyahu, read the story, above and ponder]

10.07 Nato’s bombs fall like confetti, not containing conflict but spreading it

10.07 Afghan hospital bombing: MSF demands investigation under Geneva conventions

10.07 Activists: Russia, Syria launch coordinated military attack on Assad opponents [2:13 video]

10.07 Boko Haram Has Killed 600 Nigerian Teachers, Displaced 19,000: Teachers Union [Why does the most barbaric behavior in the world have an Islamic basis?]

10.06 Will Istanbul’s new underwater highway just add traffic to a gridlocked city?

10.06 Israel demolishes homes of Palestinian attackers as clashes escalate

We are a non-profit Internet-only newspaper publication founded in 1973. Your donation is essential to our survival.

You can also mail a check to:
Baltimore News Network, Inc.
P.O. Box 42581
Baltimore, MD 21284-2581
This site Web
  Big Pharma Wins Big in Health Care Reform


Big Pharma Wins Big in Health Care Reform

by James Ridgeway
First published in his blog Unsilent Generation yesterday, 22 March 2010
To a large extent, the “debate” over health care was a show debate, an extended round of Washington smoke and mirrors. The administration early on cut its deal with Big Pharma, and pretty much stuck to it throughout the process.

The Republicans look a sour lot this morning, but the pharmaceutical industry, which helps foot the campaign bills of a sizeable chunk of members of both parties, is delighted with the legislation, and with its Democratic friends in the White House and on the Hill.

Members of Congress in both parties generally have lined up behind the insurance and pharmaceutical industries from the get go. So it should come as no surprise that the Democrats, who long ago gave up any pretence of opposing corporate power, found a way to accomodate the pharmaceutical companies on the way to its tepid reform. To a large extent, the “debate” over health care was a show debate, an extended round of Washington smoke and mirrors. The administration early on cut its deal with Big Pharma, and pretty much stuck to it throughout the process.

In fact, the Dems actually made the drugsters look good, celebrating the industry’s generous “concessions” and “discounts” while ensuring that no real threat to Big Pharma’s profits would make their way into the final bill.

The industry’s main goal from the very beginning has been to fend off any government power to negotiate or seriously regulate drug prices–and this they did.

Big Pharma’s second big win was to prevent any measure that would have opened the way for American consumers to buy less expensive drugs abroad, especially from Canada.

At the same time, the supposed give-backs by the drug industry are projected to more than pay for themselves. The much-lauded discounts on brand name drugs for seniors in the Medicare prescription drug program, for example, are good for Big Pharma because they discourage oldsters from switching to generics.

And more insured people simply mean more money coming into the coffers, for Big Pharma as well as for the insurance industry.

Confirmation of the industry analysis came early in the day from the stock market, where drug stocks initially remained level; there certainly was no rush to dump shares, which is what would be expected if the bill actually represented any threat to profits. And by 1 p, EST, CNN Money was reporting a rally in health care stocks.

“I was unable to find anything in there that would cause me to have anxiety if I were a shareholder in a pharmaceutical company,” Ira Loss, a senior health-care analyst at the research firm Washington Analysis, told Dow Jones. According to the ticker story:

Billy Tauzin, who led the industry’s negotiations on health care with lawmakers, said overall drug makers fare well. “While we’re not totally happy,” Tauzin began, “we generally feel like it tracks with our principles.”

Sanofi-Aventis SA (SNY) Chief Executive Christopher Viehbacher said in an interview that the impact of the legislation will be neutral to slightly negative “but better for the industry than if healthcare reform didn’t pass.”

Tauzin, head of the Pharmaceutical Research and Manufacturers of America or PhRMA, and Viehbacher said getting protection for brand-name biologics is among the important provisions for the industry. Drug makers pushed hard to get 12 years of exclusive market protection while the White House and some lawmakers wanted to lower the protection to seven years.

Despite fees and rebates imposed by the legislation, “analysts say drug makers will end up recouping those costs through new customers: The bill would provide insurance coverage to an additional 32 million Americans.” The Dow Jones story continues:

Chalk up another good round for Pharma and Biotech in health care reform,” began a note to clients Friday from Concept Capital, a research firm.Ken Tsuboi, co-manager of the Allianz RCM Wellness Fund, sees the impact of bill, and its $90 billion in concessions over 10 years, as relatively minor in an industry that has annual global sales of about $750 billion, with about $300 billion in the U.S., and margins close to 30%.”I think that it is actually a pretty good deal for Pharma,” Tsuboi said.

The GOP, which purports to be the party of big business, ought to be applauding at least these portions of the health care reform—and perhaps when the cameras go away, some of them will quit bitching and count their blessings. As for the obnoxious Tea Party gang, if they start threatening the real power in this country, which is vested in corporations, they may well find themselves whipped and isolated.

Born in 1936, James Ridgeway has been reporting on politics for more than 45 years. He is currently Senior Washington Correspondent for Mother Jones, and recently wrote a blog on the 2008 presidential election for the Guardian online. He previously served as Washington Correspondent for the Village Voice; wrote for Ramparts and The New Republic; and founded and edited two independent newsletters, Hard Times and The Elements.

Ridgeway is the author of 16 books, including The Five Unanswered Questions About 9/11, It’s All for Sale: The Control of Global Resources, and Blood in the Face: The Ku Klux Klan, Aryan Nations, Nazi Skinheads, and the Rise of a New White Culture. He co-directed a companion film to Blood in the Face and a second documentary film, Feed, and has co-produced web videos for GuardianFilms.

Additional information and samples of James Ridgeway’s work can be found at and at his newest web site, Solitary Watch.

This article is republished in the Baltimore Chronicle with permission of the author.

Copyright © 2010 The Baltimore News Network. All rights reserved.

Republication or redistribution of Baltimore Chronicle content is expressly prohibited without their prior written consent.

Baltimore News Network, Inc., sponsor of this web site, is a nonprofit organization and does not make political endorsements. The opinions expressed in stories posted on this web site are the authors' own.

This story was published on March 23, 2010.

Public Service Ads:
Verifiable Voting in Maryland